Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) of Extraperitoneal Abdominal Disease, is it Appropriate?

被引:0
|
作者
Mangieri, Christopher W. [1 ]
Votanopoulos, Konstantinos I. [1 ]
Shen, Perry [1 ]
Levine, Edward A. [1 ]
机构
[1] Atrium Wake Forest Baptist Med Ctr, Div Surg Oncol, Winston Salem, NC 27157 USA
关键词
COLORECTAL PERITONEAL METASTASES; SYSTEMIC CHEMOTHERAPY; DISTAL PANCREATECTOMY; RANDOMIZED-TRIAL; SURFACE MALIGNANCY; LIVER METASTASES; MANAGEMENT; CARCINOMATOSIS; RESECTION; OUTCOMES;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionCytoreductive surgery-hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) candidates often have extraperitoneal abdominal disease. Current expert peritoneal surface malignancy (PSM) guidelines recommend that the presence of extraperitoneal disease is a contraindication to CRS-HIPEC.MethodsWe conducted a retrospective review of our institutional appendiceal and colorectal CRS-HIPEC registries. Two study cohorts were constructed: (1) cytoreduction with extraperitoneal abdominal disease, and (2) cytoreductions limited to peritoneal structures alone. The primary study outcome was survival. Subgroup analysis was based on the primary tumor and completeness of cytoreduction.ResultsOverall, 864 CRS-HIPEC cases were evaluated, consisting of 578 appendiceal primaries and 286 colorectal cancers. The extraperitoneal cohort included 101 patients, with 763 patients in the non-extraperitoneal group. The median follow-up time was 13.18 years. The main analysis showed no significant differences in survival times. For overall survival (OS) there was a mean OS time of 5.87 years and a median OS time of 4.43 years for extraperitoneal cytoreductions compared with a mean of 5.90 years and a median of 4.76 years for non-extraperitoneal cytoreductions (p = 0.955). Five-year OS rates did not differ at 49.1% versus 49.5% (odds ratio [OR] 1.036, 95% confidence interval [CI] 0.671-1.597, p = 0.874). Disease-free survival (DFS) times showed a mean of 4.40 years and a median of 1.93 years for extraperitoneal cases versus a mean of 5.44 years and a median of 3.05 years for non-extraperitoneal cases (p = 0.210). Five-year DFS rates also showed no differences (OR 0.894, 95% CI 0.476-1.681, p = 0.728). No significant differences in progression-free survival (PFS)Pp times (p = 0.061) were reported. Multivariate Cox regression analysis indicated that extraperitoneal CRS was not an independent predictor of OS (hazard ratio [HR] 1.281, 95% CI 0.885-1.854, p = 0.190), DFS (HR 1.087, 95% CI 0.694-1.701, p = 0.716), or PFS (HR 0.650, 95% CI 0.243-1.738).ConclusionWe conducted the largest analysis evaluating extraperitoneal cytoreductions, with no significant differences in almost all survival outcomes. We propose that the presence of extraperitoneal abdominal disease is not a contraindication to proceeding with CRS-HIPEC.
引用
收藏
页码:2893 / 2902
页数:10
相关论文
共 50 条
  • [41] Anastomotic leakage after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer
    Feenstra, Tim Michael
    Verberne, Charlotte Julia
    Kok, Niels F. M.
    Aalbers, Arend Geert Johan
    EJSO, 2022, 48 (12): : 2460 - 2466
  • [42] Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center Experience in Austria
    Kogler Pamela
    Zitt Matthias
    Kafka-Ritsch Reinhold
    Punter Julia
    Müssigang Peter
    Perathoner Alexander
    Öfner Dietmar
    Journal of Gastrointestinal Surgery, 2018, 22 : 884 - 893
  • [43] Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis
    Nikolaos Vassos
    Thomas Förtsch
    Archil Aladashvili
    Werner Hohenberger
    Roland S. Croner
    World Journal of Surgical Oncology, 14
  • [44] Appendiceal Goblet Cell Carcinoma: Role of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
    M. Gaillard
    P. Van Eyken
    G. Verswijvel
    K. Van der Speeten
    Indian Journal of Surgical Oncology, 2023, 14 : 240 - 249
  • [45] Factors affecting dietary progression post cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Stibbard, Allysha
    Brown, Morgan
    Pons, Rachel
    Ward, Jessica
    Page, Naomi
    Stefoska-Needham, Anita
    CLINICAL NUTRITION ESPEN, 2024, 63 : 520 - 529
  • [46] Successful treatment of pseudomyxoma peritonei (PMP) through cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC): A case report and literature review
    Awad, Areej
    Awad, Mahmoud
    Alami, Muayyad
    Abu Sablan, Aseel
    Shrateh, Oadi N.
    Jubran, Fahmi
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2024, 119
  • [47] Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
    Solanki, Sohan Lal
    Mukherjee, Sudipta
    Agarwal, Vandana
    Thota, Raghu S.
    Balakrishnan, Kalpana
    Shah, Shagun Bhatia
    Desai, Neha
    Garg, Rakesh
    Ambulkar, Reshma P.
    Bhorkar, Nitin Madhukar
    Patro, Viplab
    Sinukumar, Snita
    Venketeswaran, Meenakshi V.
    Joshi, Malini P.
    Chikkalingegowda, Rajesh Holalu
    Gottumukkala, Vijaya
    Owusu-Agyemang, Pascal
    Saklani, Avanish P.
    Mehta, Sanket Sharad
    Seshadri, Ramakrishnan Ayloor
    Bell, John C.
    Bhatnagar, Sushma
    Divatia, Jigeeshu V.
    INDIAN JOURNAL OF ANAESTHESIA, 2019, 63 (12) : 972 - 987
  • [48] Implementation of a multidisciplinary Enhanced Recovery After Surgery program for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
    Stockley, Cecily
    Bouchard-Fortier, Antoine
    Mateshaytis, Jennifer
    Nelson, Gregory
    Mack, Lloyd
    Chong, Michael
    Deban, Melina
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S230 - S230
  • [49] Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
    Harper, Megan M.
    Kim, Joseph
    Pandalai, Prakash K.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (10)
  • [50] Risk of Intraoperative Hyperthermia and Outcomes in Adults Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
    Carlos E. Guerra-Londono
    Pascal Owusu-Agyemang
    German Corrales
    Marina M. Rofaeil
    Lei Feng
    Keith Fournier
    Juan P. Cata
    Annals of Surgical Oncology, 2022, 29 : 2089 - 2099